참고문헌
- Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA (2009). Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer, 115, 4470-6. https://doi.org/10.1002/cncr.24526
- Akaza H, Homma Y, Usami M, et al (2006). Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int, 98, 573-9. https://doi.org/10.1111/j.1464-410X.2006.06349.x
- Akaza H, Usami M, Hinotsu S, et al (2004). Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Cli Oncol, 34, 329-36. https://doi.org/10.1093/jjco/hyh061
- Bonkhoff H, Berges R (2009). The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol, 55, 533-42. https://doi.org/10.1016/j.eururo.2008.10.035
- Celhay O, Yacoub M, Irani J, et al (2010). Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. J Urol, 184, 2172-8. https://doi.org/10.1016/j.juro.2010.06.089
- Cho-Rok J, Yoo J, Jang YJ, et al (2006). Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology, 43, 1042-52. https://doi.org/10.1002/hep.21137
- Chung CS, Chen MH, Cullen J, et al (2008). Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology, 71, 136-40. https://doi.org/10.1016/j.urology.2007.08.028
- Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR (2003). National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst, 95, 981-9. https://doi.org/10.1093/jnci/95.13.981
- El-Naggar SM, Malik MT, Kakar SS (2007). Small interfering RNA against PTTG: a novel therapy for ovarian cancer. Int J Oncol, 31, 137-43.
- Ghayad SE, Vendrell JA, Bieche I, et al (2009). Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol, 42, 87-103.
- Hao XP, Willis JE, Pretlow TG, et al (2000). Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res, 60, 18-21.
- Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S (1999). Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med, 5, 1317-21. https://doi.org/10.1038/15275
- Heaney AP, Singson R, McCabe CJ, et al (2000). Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet, 355, 716-9. https://doi.org/10.1016/S0140-6736(99)10238-1
- Holmes Jr L, Chan W, Jiang Z, Du XL (2007). Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer. Prostate Cancer Prostatic Dis, 10, 388-95. https://doi.org/10.1038/sj.pcan.4500973
- http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.01.pdf
- Kakar SS, Malik MT (2006). Suppression of lung cancer with siRNA targeting PTTG. Int J Oncol, 29, 387-95.
- Kawakami J, Cowan JE, Elkin EP, et al (2006). Androgendeprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer, 106, 1708-14. https://doi.org/10.1002/cncr.21799
- Kim DS, Franklyn JA, Boelaert K, et al (2006). Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway. J Clin Endocrinol Metab, 91, 4603-11. https://doi.org/10.1210/jc.2006-1291
- Kwak C, Jeong SJ, Park MS, Lee E, Lee SE (2002). Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol, 168, 995-1000. https://doi.org/10.1016/S0022-5347(05)64559-4
- Labrie F, Candas B, Gomez JL, Cusan L (2002). Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology, 60, 115-9.
- Liang M, Chen X, Liu W, et al (2011). Role of the pituitary tumor transforming gene 1 in the progression of hepatocellular carcinoma. Cancer Biol Ther, 11, 337-45. https://doi.org/10.4161/cbt.11.3.14102
- Malik MT, Kakar SS (2006). Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer, 5, 61-73. https://doi.org/10.1186/1476-4598-5-61
- Pei L, Melmed S (1997). Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol, 11, 433-41. https://doi.org/10.1210/me.11.4.433
- Ramaswamy S, Ross KN, Lander ES, Golub TR (2003). A molecular signature of metastasis in primary solid tumors. Nat Genet, 33, 49-54. https://doi.org/10.1038/ng1060
- Rehfeld N, Geddert H, Atamna A, et al (2006). The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. J Carcinog, 5, 4-12. https://doi.org/10.1186/1477-3163-5-4
- Sharma A, Comstock CE, Knudsen ES, et al (2007). Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res, 67, 6192-203. https://doi.org/10.1158/0008-5472.CAN-06-4424
- Solbach C, Roller M, Eckerdt F, Peters S, Knecht R (2006). Pituitary tumor-transforming gene expression is a prognostic marker for tumor recurrence in squamous cell carcinoma of the head and neck. BMC Cancer, 6, 242-9. https://doi.org/10.1186/1471-2407-6-242
- Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M (2004). PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast, 13, 80-1. https://doi.org/10.1016/j.breast.2003.09.008
- Vlotides G, Eigler T, Melmed S (2007). Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev, 28, 165-86. https://doi.org/10.1210/er.2006-0042
- Wuttig D, Baier B, Fuessel S, et al (2009). Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer, 125, 474-82. https://doi.org/10.1002/ijc.24353
- Zhang L, Yang BX, Zhang HT, et al (2011). Prostate cancer: an emerging threat to the health of aging men in Asia. Asian J Androl, 13, 574-8. https://doi.org/10.1038/aja.2010.126
- Zhang X, Horwitz GA, Prezant TR, et al (1999). Structure, expression, and function of human pituitary tumortransforming gene (PTTG). Mol Endocrinol, 13, 156-66. https://doi.org/10.1210/me.13.1.156
- Zhou C, Liu S, Zhou X, et al (2005). Overexpression of human pituitary tumor transforming gene (hPTTG), is regulated by beta-catenin/TCF pathway in human esophageal squamous cell carcinoma. Int J Cancer, 113, 891-8. https://doi.org/10.1002/ijc.20642
- Zhu X, Mao Z, Na Y, et al (2006). Significance of pituitary tumor transforming gene 1 (PTTG1) in prostate cancer. Anticancer Res, 26, 1253-9.
- Zou H, McGarry TJ, Bernal T, Kirschner MW (1999). Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science, 285, 418-22. https://doi.org/10.1126/science.285.5426.418
피인용 문헌
- MiRNA-494 inhibits metastasis of cervical cancer through Pttg1 vol.36, pp.9, 2015, https://doi.org/10.1007/s13277-015-3440-0
- Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression vol.109, pp.3, 2018, https://doi.org/10.1111/cas.13493